126 related articles for article (PubMed ID: 10880111)
1. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate.
Kunou N; Ogura Y; Honda Y; Hyon SH; Ikada Y
J Biomed Mater Res; 2000 Sep; 51(4):635-41. PubMed ID: 10880111
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate.
Okabe J; Kimura H; Kunou N; Okabe K; Kato A; Ogura Y
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):740-4. PubMed ID: 12556407
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
[TBL] [Abstract][Full Text] [Related]
4. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device.
Okabe K; Kimura H; Okabe J; Kato A; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2702-7. PubMed ID: 12766076
[TBL] [Abstract][Full Text] [Related]
5. Effect of benzalkonium chloride on transscleral drug delivery.
Okabe K; Kimura H; Okabe J; Kato A; Shimizu H; Ueda T; Shimada S; Ogura Y
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):703-8. PubMed ID: 15671302
[TBL] [Abstract][Full Text] [Related]
6. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
Sakurai E; Nozaki M; Okabe K; Kunou N; Kimura H; Ogura Y
Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4845-52. PubMed ID: 14578407
[TBL] [Abstract][Full Text] [Related]
7. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
8. Scleral plug of biodegradable polymers for controlled drug release in the vitreous.
Hashizoe M; Ogura Y; Kimura H; Moritera T; Honda Y; Kyo M; Hyon SH; Ikada Y
Arch Ophthalmol; 1994 Oct; 112(10):1380-4. PubMed ID: 7945044
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable scleral implant for intravitreal controlled release of fluconazole.
Miyamoto H; Ogura Y; Hashizoe M; Kunou N; Honda Y; Ikada Y
Curr Eye Res; 1997 Sep; 16(9):930-5. PubMed ID: 9288455
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable scleral implant for intravitreal controlled release of ganciclovir.
Yasukawa T; Kimura H; Kunou N; Miyamoto H; Honda Y; Ogura Y; Ikada Y
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):186-90. PubMed ID: 10766290
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Evaluation of Biodegradable Scleral Plug Containing Curcumin in Rabbit Eye.
Zhang J; Sun H; Zhou N; Zhang B; Ma J
Curr Eye Res; 2017 Dec; 42(12):1597-1603. PubMed ID: 29111828
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.
De Paiva MRB; Lage NA; Guerra MCA; Mol MPG; Ribeiro MCS; Fulgêncio GO; Gomes DA; Da Costa César I; Fialho SL; Silva-Cunha A
Doc Ophthalmol; 2019 Feb; 138(1):3-19. PubMed ID: 30456454
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis.
Shin JP; Park YC; Oh JH; Lee JW; Kim YM; Lim JO; Kim SY
J Ocul Pharmacol Ther; 2009 Jun; 25(3):201-8. PubMed ID: 19456254
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity.
Souza MC; Fialho SL; Souza PA; Fulgêncio GO; Da Silva GR; Silva-Cunha A
Curr Eye Res; 2014 Jan; 39(1):99-102. PubMed ID: 24325382
[TBL] [Abstract][Full Text] [Related]
15. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide.
Kim YM; Lim JO; Kim HK; Kim SY; Shin JP
Eur J Pharm Biopharm; 2008 Sep; 70(1):179-86. PubMed ID: 18667297
[TBL] [Abstract][Full Text] [Related]
16. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis.
Kunou N; Ogura Y; Yasukawa T; Kimura H; Miyamoto H; Honda Y; Ikada Y
J Control Release; 2000 Aug; 68(2):263-71. PubMed ID: 10925134
[TBL] [Abstract][Full Text] [Related]
17. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P
Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326
[TBL] [Abstract][Full Text] [Related]
18. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits.
Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ogura Y
Graefes Arch Clin Exp Ophthalmol; 2002 Aug; 240(8):672-8. PubMed ID: 12192462
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
[TBL] [Abstract][Full Text] [Related]
20. In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device.
de Almeida FP; Saliba JB; Ribeiro JA; Siqueira RC; Fialho SL; Silva-Cunha A; Jorge R; Messias A
Doc Ophthalmol; 2015 Dec; 131(3):207-14. PubMed ID: 26576763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
